Pharma & Biotech
Case StudyAbbvie

Abbvie achieves 90% cumulative medication adherence among patients with schizophrenia using image recognition

Abbvie used AiCure’s artificial intelligence platform to visually confirm medication ingestion. This has facilitated continuous monitoring of patient treatment leading to better compliance and streamlining of clinical trials by reducing sample size.

Context

Abbvie is a biopharmaceutical company founded in 2013.

The Project

AiCure uses visual recognition to confirm medication ingestion using smartphones, and has managed to significantly increase medication adherence among patients. This was tested in patients with Schizophrenia, measured by drug concentration levels.

Results

90% medication adherence compared to 72% before.

Back to Case Studies
AI Daily Brief — leaders actually read it.

Free email — not hiring or booking. Optional BPAI updates for company news. Unsubscribe anytime.

Include

No spam. Unsubscribe anytime. Privacy policy.